The facility, named the TransEnterix Milan Robotic Surgery Center, was inaugurated yesterday in a special ceremony, the Research Triangle, N.C.-based company said.
The new facilities will feature an integrated demonstration operating theater, robotic training and development systems and be capable of hosting large groups. The center will also operate as TransEnterix’s European R&D facility.
“The Senhance Surgical Robot has strong development roots in the innovation corridor found in Lombardy and Italy. We are pleased to make this investment to create a world-class center for robotic surgical training and to continue our research and development in Milan, which will bring surgeons and researchers from across the globe together to help create the next wave of robotic surgery,” CEO Todd Pope said in a press release.
TransEnterix now produces the Senhance, which it acquired for $100 million last fall as the Telelap ALF-X device, is sold under the European Union’s CE Mark; the company is on track for an FDA decision next year. It was a timely buy, as the company shelved its flagship SurgiBot earlier this year after the FDA denied its submission for 510(k) clearance.
CEO Todd Pope spoke to MassDevice.com last month about the haptics technology in its Senhance robot-assisted surgery platform, hoping it will help it make headway against Intuitive Surgical (NSDQ:ISRG) and its 10-year lead on the market.